SCHEDULE 13G/A: Vanguard Group Amends Filing, Discloses 11.72% Stake in Edwards Lifesciences Corp

The Vanguard Group has filed an amended Schedule 13G, reporting an 11.72% beneficial ownership stake in Edwards Lifesciences Corp as of December 31, 2024.

Summary

• The Vanguard Group, a major investment adviser, has filed an Amendment No. 15 to Schedule 13G regarding its beneficial ownership in Edwards Lifesciences Corp.
• As of December 31, 2024, The Vanguard Group beneficially owned an aggregate of 69,131,602 shares of Edwards Lifesciences Corp Common Stock.
• This ownership represents 11.72% of the class of securities.
• The Vanguard Group holds 0 shares with sole voting power, 724,951 shares with shared voting power, 66,453,101 shares with sole dispositive power, and 2,678,501 shares with shared dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as it confirms a significant, passive institutional investment by a major fund manager, implying confidence in the company without any intent to disrupt management or operations.

Positives

• The Vanguard Group, a prominent institutional investor, maintains a substantial 11.72% beneficial ownership in Edwards Lifesciences Corp, indicating a significant long-term investment position.
• The filing explicitly states that Vanguard's stake was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a passive, investment-oriented approach rather than activist intent.

Future Outlook

This document, a Schedule 13G filing, does not contain any forward-looking statements or guidance from Edwards Lifesciences Corp or The Vanguard Group regarding the issuer's future performance or outlook.

Management Comments

• The Vanguard Group, through its authorized signatory, certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Edwards Lifesciences Corp.

Industry Context

The filing reflects a major institutional investor's continued significant stake in Edwards Lifesciences Corp, a leading company in the medical device sector, particularly known for its heart valve technologies. This indicates ongoing institutional confidence in the healthcare and medical technology industry, which often benefits from demographic trends and advancements in medical innovation.

Stakeholder Impact

• Shareholders: The disclosure of a significant and passive stake by The Vanguard Group may instill confidence among existing and potential shareholders, signaling institutional belief in the company's long-term prospects and stability.

Key Dates

Keywords

Edwards Lifesciences, Vanguard Group, Schedule 13G, beneficial ownership, common stock, institutional investor, medical devices, healthcare